Ftse Mib
33.707,21
-0,38%
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
61.674,11
2,34%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ALX Oncology Holdings Inc (ALXO) ALX Oncology Holdings Inc (ALXO) Notizie

ALXO

ALX Oncology (ALXO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALXO
DataOraFonteTitoloSimboloCompagnia
17/06/202422:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
06/06/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
04/06/202422:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
02/06/202416:00GlobeNewswire Inc.ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder CancerNASDAQ:ALXOALX Oncology Holdings Inc
29/05/202415:00GlobeNewswire Inc.ALX Oncology Announces Participation in the Jefferies Global Healthcare ConferenceNASDAQ:ALXOALX Oncology Holdings Inc
09/05/202422:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALXOALX Oncology Holdings Inc
09/05/202422:00GlobeNewswire Inc.ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
07/05/202415:00GlobeNewswire Inc.ALX Oncology Appoints Allison Dillon as Chief Business OfficerNASDAQ:ALXOALX Oncology Holdings Inc
30/04/202415:00GlobeNewswire Inc.ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerNASDAQ:ALXOALX Oncology Holdings Inc
24/04/202416:00GlobeNewswire Inc.ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:ALXOALX Oncology Holdings Inc
09/04/202423:30GlobeNewswire Inc.ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)NASDAQ:ALXOALX Oncology Holdings Inc
07/03/202422:03GlobeNewswire Inc.ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
05/03/202422:30GlobeNewswire Inc.ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual MeetingNASDAQ:ALXOALX Oncology Holdings Inc
03/01/202414:00GlobeNewswire Inc.ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALXOALX Oncology Holdings Inc
13/11/202322:05GlobeNewswire Inc.ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
01/11/202321:05GlobeNewswire Inc.ALX Oncology Announces November Investor Conference ParticipationNASDAQ:ALXOALX Oncology Holdings Inc
10/10/202322:05GlobeNewswire Inc.ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:ALXOALX Oncology Holdings Inc
06/10/202312:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALXOALX Oncology Holdings Inc
05/10/202314:00GlobeNewswire Inc.ALX Oncology Announces Pricing of Public OfferingNASDAQ:ALXOALX Oncology Holdings Inc
04/10/202322:10GlobeNewswire Inc.ALX Oncology Announces Proposed Public OfferingNASDAQ:ALXOALX Oncology Holdings Inc
03/10/202316:03IH Market NewsKeep An Eye Out: Pre-Market Movers And RecommendationsNASDAQ:ALXOALX Oncology Holdings Inc
03/10/202312:00GlobeNewswire Inc.ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric CancerNASDAQ:ALXOALX Oncology Holdings Inc
02/10/202322:05GlobeNewswire Inc.ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric CancerNASDAQ:ALXOALX Oncology Holdings Inc
20/09/202314:45InvestorsHub NewsWirePathways to Progress: How Orphan Drug Designation Sparks Biotech TransformationNASDAQ:ALXOALX Oncology Holdings Inc
11/09/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALXOALX Oncology Holdings Inc
08/09/202322:25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ALXOALX Oncology Holdings Inc
06/09/202314:00GlobeNewswire Inc.ALX Oncology Realigns Executive Leadership TeamNASDAQ:ALXOALX Oncology Holdings Inc
01/09/202322:11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALXOALX Oncology Holdings Inc
31/08/202313:00GlobeNewswire Inc.ALX Oncology Announces September Investor Conference ParticipationNASDAQ:ALXOALX Oncology Holdings Inc
10/08/202322:01GlobeNewswire Inc.ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program UpdateNASDAQ:ALXOALX Oncology Holdings Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALXO

La tua Cronologia

TG
700
Certara
BIT
SULE3
Solactive X3 daily short
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network